Epirubicin (hydrochloride)

Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase[1]. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity[2].

Product Specifications

CAS Number

[56390-09-1]

Product Name Alternative

4'-Epidoxorubicin (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H340, H350, H360

Target

Antibiotic; Apoptosis; DNA/RNA Synthesis; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/epirubicin-hydrochloride.html

Purity

99.62

Solubility

DMSO : 25 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O.Cl

Molecular Formula

C27H30ClNO11

Molecular Weight

579.98

Precautions

H302, H340, H350, H360

References & Citations

[1]Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4 (3) :425-39.|[2]Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56 (4) : p. 435-44.|[3]Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4 (5) : p. 359-69.|[4]Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43 (5) : p. 473-4.|[5]Kashima H, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11 (6) :e0156643.